진료과

혈액종양내과

 

전문진료분야

다발골수종, 악성림프종, 급성백혈병, 만성백혈병, 골수형성이상증후군, 재생불량성빈혈 등 혈액암 및 혈액질환

 

약력

[약력]
2019년 10월 ~ 현재 고신대학교 의과대학 내과학 교수
2007년 3월 ~ 고신대학교 복음병원 내과 전문의
2019년 9월 ~ 2021년 2월 캐나다 브리티시콜럼비아대학 교환교수
2009년 3월 ~ 2012년 2월 부산대학교 대학원 의학박사
2007년 3월 ~ 2009년 2월 고신대학교 대학원 의학석사

[교육/연구 경력]
2014년 10월 ~ 2019년 9월 고신대학교 의과대학 내과학 부교수
2010년 10월 ~ 2014년 9월 고신대학교 의과대학 내과학 조교수
2008년 10월 ~ 2010년 9월 고신대학교 의과대학 내과학 전임강사
2007년 3월 ~ 2008년 9월 고신대학교 병원 내과 전임의

[면허/자격]
2002년 2월 의사면허 취득
2007년 2월 내과 전문의 취득
2009년 10월 혈액종양내과 분과전문의 취득

 

Updated date : 2021.03.02

학회활동 및 논문

[학회활동]
대한내과학회 정회원
대한혈액학회 정회원
대한조혈모세포이식학회 정회원
American Society of Hematology 정회원
International Myeloma Society 정회원

[수상경력]
2009년 학술상 (대한암학회)
2017년 시민보건의학연구상 (부산광역시의사회)
2019년 우수논문심사자상 (대한혈액학회)

[출판된 책]
골수형성이상증후군 이야기, 엘스비어코리아 출판, 2013년 2월
림프종 바로알기, 고려의학 출판, 2017년 5월
다발골수종은 어떤 병인가요? 100문 100답 군자출판사, 2020년 6월

[주요논문 : 이외 다수]
1.Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study). Lee HS, Kim K, Kim SJ, Lee JJ, Kim I, Kim JS, Eom HS, Yoon DH, Suh C, Shin HJ, Mun YC, Kim MK, Lim SN, Choi CW, Kang HJ, Yoon SS, Min CK; Korean Multiple Myeloma Working Party (KMMWP).Lee HS, et al. Among authors: Lee JJ. Am J Hematol. 2020 Apr; 95(4):413-421.

2.Poor prognostic impact of high serum ferritin levels in patients with a lower risk of diffuse large B cell lymphoma. Kim DJ, Kim T, Jeong JY, Jo JC, Lee WS, Shin HJ, Lee JH, Lee HS.Kim DJ, et al. Among authors: Lee WS, Lee JH, Lee HS. Int J Hematol. 2020 Apr;111(4):559-566. doi: 10.1007/s12185-019-02816-6. Epub 2020 Jan 6.

3.The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study). Jo JC, Lee HS, Kim K, Lee JJ, Yoon SS, Bang SM, Kim JS, Eom HS, Yoon DH, Lee Y, Shin HJ, Park Y, Lee WS, Do YR, Mun YC, Lee MH, Kim HJ, Kim SH, Kim MK, Lim SN, Cho SH, Park SK, Yi JH, Lee JH, Kim J, Min CK; Korean Multiple Myeloma Working Party (KMMWP).Jo JC, et al. Among authors: Lee HS, Lee JJ, Lee Y, Lee WS, Lee MH, Lee JH. Ann Hematol. 2020 Feb;99(2):309-319. doi: 10.1007/s00277-019-03904-7. Epub 2019 Dec 23.

4.Incidence, prevalence, mortality, and causes of death in Waldenstr?m macroglobulinemia in Korea: A nationwide, population-based study : Jeong S, Kong SG, Kim DJ, Lee S, Lee HS. BMC Cancer. 2020 Jul 3;20(1):623.

5.Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study. Jeong S, Park YJ, Yun W, Lee ST, Choi JR, Suh C, Jo JC, Cha HJ, Jeong JY, Chang H, Cha YJ, Kim H, Park MJ, Song W, Cho EH, Jeong EG, Lee J, Park Y, Lee YS, Kim DJ, Lee HS. Sci Rep. 2020 Aug 7;10(1):13359.

6.Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Lee HS, Kim K, Lee JJ, Yoon SS, Bang SM, Kim JS, Eom HS, Yoon DH, Lee Y, Shin HJ, Park Y, Jo JC, Lee WS, Do YR, Mun YC, Lee MH, Kim HJ, Kim SH, Kim MK, Lim SN, Park SK, Yi JH, Lee JH, Min CK; Korean Multiple Myeloma Working Party (KMMWP). Int J Hematol. 2021 Jan;113(1):81-91. doi: 10.1007/s12185-020-02988-6. Epub 2020 Sep 5.

7.Early transplantation-related mortality after allogeneic hematopoietic stem cell transplantation in patients with acute leukemia. Kong SG, Jeong S, Lee S, Jeong JY, Kim DJ, Lee HS. BMC Cancer. 2021 Feb 18;21(1):177.

8.Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial. Lee JH, Park Y, Kang KW, Lee JJ, Lee HS, Eom HS, Do YR, Kim JS, Yoon SS, Shin DY, Koh Y, Kim KH, Lee WS, Jo JC, Lee YJ, Lee JY, Kim DS, Shim H, Chang MH, Kim SH, Min CK; Korean multiple myeloma working party [KMMWP].Lee JH, et al. Among authors: lee hs. Ann Hematol. 2021 Jan 15. doi: 10.1007/s00277-021-04407-0. Online ahead of print.Ann Hematol. 2021.

9.Incidence of malignancy and related mortality after kidney transplantation: a nationwide, population-based cohort study in Korea. Jeong S, Lee HS, Kong SG, Kim DJ, Lee S, Park MJ, Song W, Rim JH, Kim HJ.Jeong S, et al. Among authors: lee hs. Sci Rep. 2020 Dec 8;10(1):21398. doi: 10.1038/s41598-020-78283-5.Sci Rep. 2020.

10.The risk factors associated with treatment-related mortality in 16,073 kidney transplantation-A nationwide cohort study. Choi H, Lee W, Lee HS, Kong SG, Kim DJ, Lee S, Oh H, Kim YN, Ock S, Kim T, Park MJ, Song W, Rim JH, Lee JH, Jeong S.Choi H, et al. Among authors: lee hs. PLoS One. 2020 Jul 28;15(7):e0236274. doi: 10.1371/journal.pone.0236274. eCollection 2020.PLoS One. 2020.

11.Prognostic significance of interim PET/CT response for the treatment of advanced-stage marginal zone lymphoma in the post-rituximab era. Song GY, Yoon SE, Kim SJ, Kim JS, Koh Y, Moon JH, Oh SY, Lee HS, Shin HJ, Do YR, Lee WS, Kim DS, Park Y, Yhim HY, Yang DH.Song GY, et al. Among authors: lee hs. Sci Rep. 2020 Jul 15;10(1):11649. doi: 10.1038/s41598-020-68310-w.Sci Rep. 2020.

12.Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis. Song GY, Jung SH, Lee JJ, Kim JS, Min CK, Kim K, Choi Y, Eom HS, Joo YD, Kim SH, Kwak JY, Kang HJ, Lee JH, Lee HS, Mun YC, Moon JH, Sohn SK, Park SK, Park Y, Shin HJ, Yoon SS.Song GY, et al. Among authors: lee hs. Leuk Lymphoma. 2020 Nov;61(11):2714-2721. doi: 10.1080/10428194.2020.1783448. Epub 2020 Jun 25.Leuk Lymphoma. 2020.

13.Treatment with intravenous busulfan, melphalan, and etoposide followed by autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: a multicenter study from the consortium for improving survival of lymphoma. Kim KH, Kim WS, Kim SJ, Yoon DH, Suh C, Kang HJ, Choi CW, Lee HS, Bae SH, Park J, Park EK, Kwak JY, Lee MH, Kang BW, Park SK, Won JH.Kim KH, et al. Among authors: lee hs. Transpl Int. 2020 Oct;33(10):1211-1219. doi: 10.1111/tri.13664. Epub 2020 Jul 23.Transpl Int. 2020.

14.Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis. Hong JY, Yoon DH, Yoon SE, Kim SJ, Lee HS, Eom HS, Lee HW, Shin DY, Koh Y, Yoon SS, Jo JC, Kim JS, Kim SJ, Cho SH, Lee WS, Won JH, Kim WS, Suh C. Sci Rep. 2019 Dec 30;9(1):20302.

15.Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for Improving Survival of Lymphoma report. Jo JC, Kim SJ, Lee HS, Eom HS, Lee SI, Park Y, Lee JO, Lee Y, Yhim HY, Yang DH, Byun JM, Kang HJ, Kim HJ, Shin HJ, Yoo KH, Suh C; and Consortium for Improving Survival of Lymphoma (CISL). Ann Hematol. 2020 Feb;99(2):223-228.

16.Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma. Kim SJ, Yoon DH, Kang HJ, Hong JY, Lee HS, Oh SY, Shin HJ, Kong JH, Yi JH, Sakamoto K, Ko YH, Huh J, Lee SS, Takeuchi K, Shin DY, Suh C, Kim WS. BMC Cancer. 2019 Nov 10;19(1):1080.

17.Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study. Oh SY, Kim WS, Kim JS, Kim SJ, Yoon DH, Yang DH, Lee WS, Kim HJ, Yhim HY, Jeong SH, Won JH, Lee S, Kong JH, Lim SN, Ji JH, Kwon KA, Lee GW, Lee JH, Lee HS, Shin HJ, Suh C. Cancer Commun (Lond). 2019 Oct 16;39(1):58.

18.Echinochrome A Promotes Ex Vivo Expansion of Peripheral Blood-Derived CD34+ Cells, Potentially through Downregulation of ROS Production and Activation of the Src-Lyn-p110δ Pathway. Park GB, Kim MJ, Vasileva EA, Mishchenko NP, Fedoreyev SA, Stonik VA, Han J, Lee HS, Kim D, Jeong JY. Mar Drugs. 2019 Sep 9;17(9).

19.Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma. Lee YJ, Moon JH, Sohn SK, Kim SJ, Jung SH, Lee JJ, Jo JC, Shin HJ, Lee WS, Lee JH, Bae SH, Kim MK, Lee HS, Kim K, Min CK; Korean Multiple Myeloma Working Party. Bone Marrow Transplant. 2019 Dec;54(12):2051-2059.

20.First case report of latent tuberculosis reactivation complicating treatment with nilotinib in chronic myeloid leukemia. Kim DJ, Jeong S, Kong SG, Lee HS. Blood Res. 2019 Jun;54(2):151-153.

21.The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores. Huh SJ, Oh SY, Lee S, Lee JH, Kim SH, Lee GW, Kim SJ, Kim WS, Lee HS, Jo JC, Kim MJ, Kwon JH, Kim HJ. Int J Hematol. 2019 Oct;110(4):438-446.

22.Lenalidomide as a second-line therapy after failure of hypomethylating agents in patients with myelodysplastic syndrome. Kim H, Lee JH, Lee WS, Kim I, Moon JH, Choi CW, Lee HS, Park J, Choi Y, Shin HJ, Cho SH, Kim KH, Kim SY, Kim YJ; Korean Society of Haematology AML/MDS Working Party. Br J Haematol. 2019 Sep;186(5):e151-e155.

23.Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome. Park S, Baek DW, Sohn SK, Ahn JS, Kim HJ, Shin HJ, Chung JS, Lee SM, Lee WS, Lim SN, Lee YJ, Choi Y, Lee HS, Cho YY, Lee GW, Moon JH. Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e367-e373.

24.The effects of erythropoiesis-stimulating agents on the management of chemotherapy-induced anemia and tumor growth in diffuse large B-cell lymphoma patients. Park LC, Song YJ, Kim DJ, Kim MJ, Jo JC, Lee WS, Shin HJ, Oh SY, Do YR, Jeong JY, Lee HS; Consortium for Improving Survival of Lymphoma (CISL). Int J Cancer. 2019 Nov 1;145(9):2459-2467.

25.Clinical impact of anti-thymocyte globulin on survival and graft-versus-host disease in patients undergoing human leukocyte antigen mismatched allogeneic stem cell transplantation. Kim T, Choi Y, Lee JH, Park S, Ahn JS, Moon JH, Shin HJ, Lee WS, Kim D, Lee HS. Korean J Intern Med. 2019 Jan 10.

26.Multicenter Phase 2 Study of Reduced-Dose CHOP Chemotherapy Combined With Rituximab for Elderly Patients With Diffuse Large B-Cell Lymphoma. Park S, Jo JC, Do YR, Yang DH, Lim SN, Lee WS, Kim WS, Lee HS, Hong DS, Kim HJ, Shin HJ. Clin Lymphoma Myeloma Leuk. 2019 Mar;19(3):149-156.

27.Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone. Shin J, Lee JJ, Kim K, Min CK, Lee JO, Suh C, Kim JS, Lee YJ, Yoon SS, Jo JC, Lee HS, Bang SM; Korean Multiple Myeloma 151 Investigators. Int J Hematol. 2018 Oct 5.

28.The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma. Lee GW, Park SW, Go SI, Kim HG, Kim MK, Min CK, Kwak JY, Bae SB, Yoon SS, Lee JJ, Kim KH, Nam SH, Mun YC, Kim HJ, Bae SH, Shin HJ, Lee JH, Park JS, Jeong SH, Lee MH, Lee HS, Park KW, Lee WS, Lee SM, Lee JO, Hyun MS, Jo DY, Lim SN, Lee JH, Kim H, Cho DY, Do YR, Kim JA, Park SK, Kim JS, Kim SJ, Yi HG, Moon JH, Choi CW, Kim SH, Kim BS, Park MR, Shim H, Song MK, Kim Y, Kim K. Acta Haematol. 2018 Sep 25;140(3):146-156.

29.Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts. Baek DW, Lee YJ, Kim H, Ahn SY, Ahn JS, Shin HJ, Lee WS, Lee SM, Song IC, Lee HS, Park SW, Choi Y, Cho YY, Bae SH, Kim HJ, Sohn SK, Moon JH. Ann Hematol. 2018 Aug 2.

30.Synergistic Integration of Mesenchymal Stem Cells and Hydrostatic Pressure in the Expansion and Maintenance of Human Hematopoietic/Progenitor Cells. Kang YG, Jeong JY, Lee TH, Lee HS, Shin JW. Stem Cells Int. 2018 Feb 27

31.Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis. Hong JY, Yoon DH, Suh C, Kim WS, Kim SJ, Jo JC, Kim JS, Lee WS, Oh SY, Park Y, Kim SY, Lee MH, Lee HS, Do YR. Ann Hematol. 2018 Aug;97(8):1437-1443

32.Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150). Jung SH, Lee JJ, Kim JS, Min CK, Kim K, Choi Y, Eom HS, Joo YD, Kim SH, Kwak JY, Kang HJ, Lee JH, Lee HS, Mun YC, Moon JH, Sohn SK, Park SK, Park Y, Shin HJ, Yoon SS; Korean Multiple Myeloma Working Party. Biol Blood Marrow Transplant. 2018 May;24(5):923-929.

33.Role of thymoglobulin in matched sibling allogeneic hematopoietic stem cell transplantation with busulfan and fludarabine conditioning in myeloid malignanicies. Shin DY, Lee JH, Park S, Lee JO, Moon JH, Ahn JS, Choi Y, Song IC, Shin HJ, Lee WS, Lee HS, Yoon SS. Bone Marrow Transplant. 2017 Oct 30.

34.No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome. Sohn SK, Moon JH, Lee IH, Ahn JS, Kim HJ, Chung JS, Shin HJ, Park SW, Lee WS, Lee SM, Kim H, Lee HS, Kim YS, Cho YY, Bae SH, Lee JH, Kim SH, Song IC, Kwon JH, Lee YJ. Korean J Intern Med. 2017 Dec 15

35.Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy. Oh SB, Park SW, Chung JS, Lee WS, Lee HS, Cho SH, Choi YS, Lim SN, Shin HJ; Hematology Association of South-East Korea (HASEK) study group. Ann Hematol. 2017 Nov;96(11):1801-1809.

36.Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma. Hong J, Kim SJ, Chang MH, Kim JA, Kwak JY, Kim JS, Yoon DH, Lee WS, Do YR, Kang HJ, Eom HS, Park Y, Won JH, Mun YC, Kim HJ, Kwon JH, Kong JH, Oh SY, Lee S, Bae SH, Yang DH, Jun HJ, Lee HS, Yun HJ, Lee SI, Kim MK, Yi JH, Lee JH, Kim WS, Suh C. Oncotarget. 2017 Sep 18;8(54):92171-92182.

37.The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). Jung SH, Lee JJ, Kim K, Suh C, Yoon DH, Min CK, Sohn SK, Choi CW, Lee HS, Kim HJ, Shin HJ, Bang SM, Yoon SS, Park SK, Yhim HY, Kim MK, Jo JC, Mun YC, Lee JH, Kim JS; Korean Multiple Myeloma Working Party. Oncotarget. 2017 Jun 16;8(45):79517-79526

38.Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party. Kim DJ, Lee HS, Moon JH, Sohn SK, Kim HJ, Cheong JW, Jo DY, Kim H, Lee H, Bang SM, Lee WS, Park Y, Lee MH, Lee JH, Bae SH, Kim MK; Korean Society of Hematology AML/MDS Working Party. Oncotarget. 2017 May 29

39.Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial. Seo J, Kim WS, Kim JS, Kim SJ, Lee JH, Hong JS, Lee GW, Oh SY, Lee JH, Yoon DH, Lee WS, Kim HJ, Kwak JY, Kang HJ, Jo JC, Park Y, Lee HS, Kim HJ, Suh C. Blood Res. 2017 Sep;52(3):200-206

40.Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy. Cho H, Yoon DH, Lee JB, Kim SY, Moon JH, Do YR, Lee JH, Park Y, Lee HS, Eom HS, Shin HJ, Min CK, Kim JS, Jo JC, Kang HJ, Mun YC, Lee WS, Lee JJ, Suh C, Kim K; and the Korean Multiple Myeloma Working Party. Am J Hematol. 2017 Dec;92(12):1280-1286

41.Benefits of hypomethylating therapy in IPSS lower-risk myelodysplastic syndrome patients: A retrospective multicenter case series study. Lee JH, Kim YJ, Sohn SK, Yoon SS, Kim H, Cheong JW, Lee WS, Lee GW, Lim SN, Kim MK, Lee HS, Kim HJ; AML MDS Working Party of the Korean Society of Hematology. Leuk Res. 2017 Sep;60:135-144.

42.A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma. Kim MK, Kim K, Min CK, Kwak JY, Bae SB, Yoon SS, Lee JJ, Kim KH, Nam SH, Mun YC, Kim HJ, Bae SH, Shin HJ, Lee JH, Park JS, Jeong SH, Lee MH, Kim YS, Lee HS, Park KW, Lee WS, Lee SM, Lee JO, Hyun MS, Jo DY, Lim SN, Lee JH, Cho DY, Do YR, Kim JA, Park SK, Kim JS, Kim SJ, Kim H, Yi HG, Moon JH, Choi CW, Kim SH, Joo YD, Kim HG, Kim BS, Park MR, Song MK, Kim SY. Oncotarget. 2017 Jun 6

43.Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice. Lee HS, Min CK. Korean J Intern Med. 2016 Sep;31(5):809-19.

44.Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes. Lee YJ, Park SW, Lee IH, Ahn JS, Kim HJ, Chung JS, Shin HJ, Lee WS, Lee SM, Joo YD, Kim H, Lee HS, Kim YS, Cho YY, Moon JH, Sohn SK. Ann Hematol. 2016 Oct;95(11):1795-804.

45.The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea. Lee HS, Min CK, Lee JJ, Kim K, Kim SJ, Yoon DH, Eom HS, Lee H, Lee WS, Shin HJ, Lee JH, Park Y, Jo JC, Do YR, Mun YC, Lee MH; Korean Multiple Myeloma Working Party (KMMWP). Ann Hematol. 2016 May;95(6):911-9.

46.Clinical Features and Survival of Patients With Follicular Lymphoma in Korea. Cho SH, Suh C, Do YR, Lee JJ, Yun HJ, Oh SY, Lee HS, Cho SG, Cho IS, Lee WS, Won YW, Kim HJ, Lee HG, Lee SI, Lim SN, Sohn BS, Ahn HJ, Chang MH, Kwon KA, Kim WS. Clin Lymphoma Myeloma Leuk. 2016 Apr;16(4):197-202.

47.Peripheral T cell lymphomas in elderly patients: a retrospective analysis from the Hematology Association of South East Korea (HASEK). Jo JC, Choi Y, Shin HJ, Yhim SN, Lee HS, Lee WS, Lee JH, Kim H, Oh SY. Ann Hematol. 2016 Mar;95(4):619-24.

48.Prediction of survival by applying current prognostic models in diffuse large B-cell lymphoma treated with R-CHOP followed by autologous transplantation. Lee HG, Kim SY, Kim I, Kim YK, Kim JA, Kim YS, Lee HS, Park J, Kim SJ, Shim H, Eom HS, Park BB, Lee J, Park SK, Cheong JW, Park KW. Blood Res. 2015 Sep;50(3):160-6

49.The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea. Kim C, Lee HS, Min CK, Lee JJ, Kim K, Yoon DH, Eom HS, Lee H, Lee WS, Shin HJ, Lee JH, Park Y, Jo JC, Do YR, Mun YC. Korean J Intern Med. 2015 Sep;30(5):675-83.

50.Induction chemotherapy followed by up-front autologous stem cell transplantation may have a survival benefit in high-risk diffuse large B-cell lymphoma patients. Shin HJ, Yoon DH, Lee HS, Oh SY, Yang DH, Kang HJ, Chong SY, Park Y, Do Y, Lim SN, Jo JC, Lee WS, Chung JS; Consortium for Improving Survival of Lymphoma. Exp Hematol. 2016 Jan;44(1):3-13.

51.Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Kim DY, Joo YD, Lim SN, Kim SD, Lee JH, Lee JH, Kim DH, Kim K, Jung CW, Kim I, Yoon SS, Park S, Ahn JS, Yang DH, Lee JJ, Lee HS, Kim YS, Mun YC, Kim H, Park JH, Moon JH, Sohn SK, Lee SM, Lee WS, Kim KH, Won JH, Hyun MS, Park J, Lee JH, Shin HJ, Chung JS, Lee H, Eom HS, Lee GW, Cho YU, Jang S, Park CJ, Chi HS, Lee KH; Adult Acute Lymphoblastic Leukemia Working Party of the Korean Society of Hematology. Blood. 2015 Aug 6;126(6):746-56.

52.Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload. Kim IH, Moon JH, Lim SN, Sohn SK, Kim HG, Lee GW, Kim YS, Lee HS, Kwon KY, Kim SH, Park KT, Chung JS, Lee WS, Lee SM, Hyun MS, Kim H, Ryoo HM, Bae SH, Joo YD. Transfusion. 2015 Jul;55(7):1613-20.

53.Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis. Hong J, Kim SJ, Ahn JS, Song MK, Kim YR, Lee HS, Yhim HY, Yoon DH, Kim MK, Oh SY, Park Y, Mun YC, Do YR, Ryoo HM, Lee JJ, Lee JH, Kim WS, Suh C. Cancer Res Treat. 2015 Apr;47(2):173-81.

54.Multicenter analysis of treatment outcomes in adult patients with lymphoblastic lymphoma who received hyper-CVAD induction followed by hematopoietic stem cell transplantation.Jeong SH, Moon JH, Kim JS, Yang DH, Park Y, Cho SG, Kwak JY, Eom HS, Won JH, Hong JS, Oh SY, Lee HS, Kim SJ. Ann Hematol. 2015 Apr;94(4):617-25. doi: 10.1007/s00277-014-2258-y. Epub 2014 Dec 3.

55.Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma. Shin HJ, Lee WS, Lee HS, Kim H, Lee GW, Song MK, Kim JS, Yhim HY, Chung JS. Leuk Lymphoma. 2014 Nov;55(11):2490-6.

56.Clinical Usefulness of Hydromorphone-OROS in Improving Sleep Disturbances in Korean Cancer Patients: A Multicenter, Prospective, Open-Label Study.Shin SH, Lee HS, Kim YS, Choi YJ, Kim SH, Kwon HC, Oh SY, Kang JH, Sohn CH, Lee SM, Baek JH, Min YJ, Kim C, Chung JS. Cancer Res Treat. 2014 Oct;46(4):331-8. doi: 10.4143/crt.2013.130. Epub 2014 Jul 21.

57.R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma.Lee HG, Choi Y, Kim SY, Kim I, Kim YK, Kim YS, Lee HS, Kim SJ, Kim JA, Park BB, Park J, Shim H, Eom HS, Lee J, Park SK, Cheong JW, Park KW. Blood Res. 2014 Jun;49(2):107-14. doi: 10.5045/br.2014.49.2.107. Epub 2014 Jun 25.

58.Clinical factors associated with response or survival after chemotherapy in patients with Waldenstr?m macroglobulinemia in Korea.Lee HS, Kim K, Yoon DH, Kim JS, Bang SM, Lee JO, Eom HS, Lee H, Kim I, Lee WS, Bae SH, Kim SH, Lee MH, Do YR, Lee JH, Hong J, Shin HJ, Lee JH, Mun YC, Min CK. Biomed Res Int. 2014;2014:253243. doi: 10.1155/2014/253243. Epub 2014 Jun 4.

59.Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma.Shin HJ, Kim K, Lee JW, Song MK, Lee JJ, Lee HS, Lee WS, Kim SJ, Chung JS. Eur J Haematol. 2014 Nov;93(5):414-21. doi: 10.1111/ejh.12377. Epub 2014 Jun 14.

60.Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma.Kang BW, Sohn SK, Moon JH, Chae YS, Kim JG, Lee SJ, Kim WS, Lee JJ, Lee SR, Park KU, Lee HS, Lee WS, Won JH, Park MR, Kwak JY, Kim MK, Kim HJ, Oh SY, Kang HJ, Suh C. Blood Res. 2014 Mar;49(1):15-21. doi: 10.5045/br.2014.49.1.15. Epub 2014 Mar 24.

61.The prognostic significance of elevated levels of serum ferritin before chemotherapy in patients with non-Hodgkin lymphoma.Yoh KA, Lee HS, Park LC, Lee EM, Shin SH, Park DJ, Ye BJ, Kim YS. Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):43-9. doi: 10.1016/j.clml.2013.09.008. Epub 2013 Oct 1.

62.High-dose etoposide plus granulocyte colony-stimulating factor as an effective chemomobilization regimen for autologous stem cell transplantation in patients with non-Hodgkin Lymphoma previously treated with CHOP-based chemotherapy: a study from the Consortium for Improving Survival of Lymphoma.Hyun SY, Cheong JW, Kim SJ, Min YH, Yang DH, Ahn JS, Lee WS, Ryoo HM, Do YR, Lee HS, Lee JH, Oh SY, Suh C, Yhim HY, Kim JS. Biol Blood Marrow Transplant. 2014 Jan;20(1):73-9. doi: 10.1016/j.bbmt.2013.10.012. Epub 2013 Oct 17.

63.Predictive factors for rapid neutrophil and platelet engraftment after allogenic peripheral blood stem cell transplantation in patients with acute leukemia.Lee HS, Park LC, Lee EM, Shin SH, Kim YS, Moon JH, Lee WS, Shin HJ, Kim MH, Ye BJ, Chung JS. Ann Hematol. 2013 Dec;92(12):1685-93. doi: 10.1007/s00277-013-1847-5. Epub 2013 Jul 30.

64.Current routine practice and clinico-pathological characteristics associated with acute promyelocytic leukemia in Korea.Ahn S, Park JS, Jeong SH, Lee HW, Park JE, Kim MH, Kim YS, Lee HS, Park TS, You E, Rheem I, Park J, Huh JY, Kang MS, Cho SR. Blood Res. 2013 Mar;48(1):31-4. doi: 10.5045/br.2013.48.1.31. Epub 2013 Mar 25.

65.Prognostic value of Waldeyer's ring involvement of diffuse large B-cell lymphoma treated with R-CHOP.Oh MY, Chung JS, Song MK, Shin HJ, Lee HS, Lee SM, Lee GW, Lee SE. Int J Hematol. 2013 Mar;97(3):397-402. doi: 10.1007/s12185-013-1282-3. Epub 2013 Feb

66.Early Response to Bortezomib Combined Chemotherapy Can Help Predict Survival in Patients with Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation. Lee HS, Kim YS, Kim K, Kim JS, Kim HJ, Min CK, Suh C, Eom HS, Yoon SS, Lee JH, Kim MK, Kim SH, Bae SH, Mun YC, Jo DY, Chung JS; The Korean Multiple Myeloma Working Party (KMMWP). J Korean Med Sci. 2013 Jan;28(1):80-86. Epub 2013 Jan 8.

67.Comparison of Therapeutic Outcomes Between Surgical Resection Followed By R-CHOP and R-CHOP Alone for Localized Primary Intestinal Diffuse Large B-cell Lymphoma. Lee HS, Park LC, Lee EM, Shin SH, Ye BJ, Oh SY, Song MK, Lee SM, Lee WS, Kang BW, Chang MH, Cho SG, Yahng SA, Yoon SS, Kwon JH, Kim YS. Am J Clin Oncol. 2012 Dec 1.

68.Waldeyer's ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal? A study by the Consortium for Improving Survival of Lymphoma (CISL). Oh SY, Kim WS, Kim JS, Kim SJ, Lee S, Lee DH, Lee SI, Kang HJ, Choi CW, Park J, Song MK, Kim HJ, Kwon JH, Kwak JY, Bae SH, Park BB, Do YR, Lee HS, Jeong SH, Suh C, Kim HJ. Int J Hematol. 2012 Nov;96(5):631-7.

69.Clinical value of metabolic tumor volume by PET/CT in extranodal natural killer/T cell lymphoma. Song MK, Chung JS, Shin HJ, Moon JH, Ahn JS, Lee HS, Lee SM, Lee GW, Kim SJ, Lee SM. Leuk Res. 2013 Jan;37(1):58-63. doi: 10.1016/j.leukres.2012.09.011. Epub 2012 Oct 3.

70.Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer. Park LC, Lee HS, Shin SH, Park SJ, Park MI, Oh SY, Kwon HC, Baek JH, Choi YJ, Kang MJ, Kim YS. World J Gastroenterol. 2012 Mar 14;18(10):1104-9.

71.Cyclophosphamide-containing regimen (TCD) is superior to melphalan-containing regimen (MPT) in elderly multiple myeloma patients with renal impairment. Song MK, Chung JS, Shin HJ, Moon JH, Lee JJ, Yoon SS, Kim JS, Lee JO, Do YR, Lee HS, Park EK; Korean Multiple Myeloma Working Party. Ann Hematol. 2012 Jan 13.

72.Prognostic value of metabolic tumor volume on PET?/?CT in primary gastrointestinal diffuse large B cell lymphoma. Song MK, Chung JS, Shin HJ, Moon JH, Lee JO, Lee HS, Lee SM, Lee GW, Lee SE, Kim SJ. Cancer Sci. 2012 Mar;103(3):477-482. doi: 10.1111/j.1349-7006.2011.02164.x. Epub 2012 Jan 16.

73.Incidence rates and risk factors for vascular events in patients with essential thrombocythemia: a multicenter study from Korea. Lee HS, Park LC, Lee EM, Lee SJ, Shin SH, Im H, Do KM, Kim EJ, Ye BJ, Song MK, Kim SH, Lee SM, Lee WS, Kim YS. Clin Lymphoma Myeloma Leuk. 2012 Feb;12(1):70-5. Epub 2011 Nov 16.

74.Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Song MK, Chung JS, Shin HJ, Lee SM, Lee SE, Lee HS, Lee GW, Kim SJ, Lee SM, Chung DS. Ann Hematol. 2011 Nov 11.

75.Successful Chemotherapy Following Autologous Stem Cell Transplantation in Multiple Myeloma and Multi-organ Dysfunction with Infiltration of Eosinophils: A Case Report. Lee HS, Park LC, Shin SH, Lee SU, Chang HK, Huh B, Jung GS, Kim MH, Kim YS.Cancer Res Treat. 2011 Sep;43(3):199-203. Epub 2011 Sep 30.

76.Herpesviridae viral infections after chemotherapy without antiviral prophylaxis in patients with malignant lymphoma: incidence and risk factors. Lee HS, Park JY, Shin SH, Kim SB, Lee JS, Lee A, Ye BJ, Kim YS. Am J Clin Oncol. 2012 Apr;35(2):146-50.

77.Herpesviridae viral infections following rituximab combined chemotherapy in patients with diffuse large B-cell lymphoma. Park LC, Lee HS, Shin SH, Im H, Ye BJ, Song MK, Oh SY, Lee SM, Lee WS, Kim YS. Acta Haematol. 2011;125(4):230-6. Epub 2011 Feb 12.

78.Incidence and clinical characteristics of clonal cytogenetic abnormalities of acquired aplastic anemia in adults.Lee JH, Kwon KA, Lee S, Oh SY, Kim SH, Kwon HC, Han JY, Song MK, Chung JS, Lee HS, Kim YS, Lee SM, Joo YD, Kim HJ. Korean J Hematol. 2010 Dec;45(4):242-6. Epub 2010 Dec 31.

79.Effects of Helicobacter pylori eradication in patients with immune thrombocytopenic purpura. Tag HS, Lee HS, Jung SH, Kim BK, Kim SB, Lee A, Lee JS, Shin SH, Kim YS. Korean J Hematol. 2010 Jun;45(2):127-32. Epub 2010 Jun 30.

80.Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study. Oh SY, Kim WS, Kim JS, Kim SJ, Lee S, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Chae YS, Yang DH, Kang HJ, Choi CW, Park J, Kim HJ, Kwon JH, Lee HS, Lee GW, Eom HS, Kwak JY, Lee WS, Suh C, Kim HJ. Int J Hematol. 2010 Oct;92(3):510-7. Epub 2010 Sep 14.

81.Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study. Oh SY, Kim WS, Kim JS, Kim SJ, Lee S, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Chae YS, Yang DH, Kang HJ, Choi CW, Park J, Kim HJ, Kwon JH, Lee HS, Lee GW, Eom HS, Kwak JY, Suh C, Kim HJ. Cancer Sci. 2010 Nov;101(11):2443-7.

82.Clinical value of absolute lymphocyte counts before bortezomib-dexamethasone therapy in relapsed multiple myeloma patients. Song MK, Chung JS, Joo YD, Lee SM, Lee GW, Lee HS, Kim SH, Yun EY, Seol YM, Kim SG, Shin HJ, Choi YJ, Cho GJ. Acta Haematol. 2010;124(1):34-9. Epub 2010 Jul 3.

83.Clinical correlation between brain natriutetic peptide and anthracyclin-induced cardiac toxicity. Lee HS, Son CB, Shin SH, Kim YS. Cancer Res Treat. 2008 Sep;40(3):121-6. Epub 2008 Sep 30.

84.Clinical significance of GSTM1 and GSTT1 polymorphisms in younger patients with acute myeloid leukemia of intermediate-risk cytogenetics. Lee HS, Lee JH, Hur EH, Lee MJ, Lee JH, Kim DY, Kim SH, Seol M, Kang SI, Ryu SG, Kang YA, Lee YS, Kang MJ, Seo EJ, Kim YS, Chi HS, Park CJ, Jang S, Yun SC, Lee KH. Leuk Res. 2009 Mar;33(3):426-33. Epub 2008 Aug 29.